News Category
BIOT's non-exclusive appointment by CelSiege Biosciences to represent the IN01 cancer immunotherapy in Japan and China signals a strategic push to add...
New research published in JCI Insight suggests that GeoVax's Gedeptin therapy could enhance immune checkpoint inhibitor responses and activate systemi...
CEL-SCI Corporation closed a $7.2 million public offering to fund continued development of its cancer immunotherapy Multikine and for general corporat...
